These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Hillery CA; Du MC; Wang WC; Scott JP Br J Haematol; 2000 May; 109(2):322-7. PubMed ID: 10848818 [TBL] [Abstract][Full Text] [Related]
30. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628 [TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220 [TBL] [Abstract][Full Text] [Related]
33. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Almeida CB; Scheiermann C; Jang JE; Prophete C; Costa FF; Conran N; Frenette PS Blood; 2012 Oct; 120(14):2879-88. PubMed ID: 22833547 [TBL] [Abstract][Full Text] [Related]
34. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil. Silva-Pinto AC; Angulo IL; Brunetta DM; Neves FI; Bassi SC; Santis GC; Covas DT Sao Paulo Med J; 2013; 131(4):238-43. PubMed ID: 24141294 [TBL] [Abstract][Full Text] [Related]
35. Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Joneckis CC; Ackley RL; Orringer EP; Wayner EA; Parise LV Blood; 1993 Dec; 82(12):3548-55. PubMed ID: 7505118 [TBL] [Abstract][Full Text] [Related]
36. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325 [TBL] [Abstract][Full Text] [Related]
37. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965 [TBL] [Abstract][Full Text] [Related]
38. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747 [TBL] [Abstract][Full Text] [Related]
39. Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium. Elion JE; Brun M; Odièvre MH; Lapouméroulie CL; Krishnamoorthy R Hematol J; 2004; 5 Suppl 3():S195-8. PubMed ID: 15190308 [No Abstract] [Full Text] [Related]
40. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Charache S Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]